At present, olverembatinib has been approved in China for the treatment of adult patients with TKI-resistant chronic-phase chronic myeloid leukemia (CML-CP) or accelerated-phase CML (CML-AP) harboring ...
This pathway approach revealed that 1) 13 proteins were conserved, whereas five lacked data sufficient to determine specific critical amino acids; 2) variation in protein-protein interfaces is ...
SOUTH SAN FRANCISCO, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that Sean ...
Disclaimer: AlphaGalileo is not responsible for the accuracy of news releases posted to AlphaGalileo by contributing institutions or for the use of any information through the AlphaGalileo system.
At The Liver Meeting 2024, Arbutus Biopharma Corp. presented data from the phase IIa Im-prove study showing its RNAi drug, imdusiran, in combination with pegylated interferon alfa-2α and nucleos(t)ide ...